MerrynM.VoyseyMerrynM. i inni, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, „The Lancet”, 397 (10269), 2021, s. 99–111, DOI: 10.1016/S0140-6736(20)32661-1, ISSN0140-6736, PMID: 33306989, PMCID: PMC7723445 [dostęp 2021-02-04](ang.).
Pedro MP.M.FolegattiPedro MP.M. i inni, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial”., „The Lancet”, 396 (10249), 2020, s. 467–478, DOI: 10.1016/S0140-6736(20)31604-4, PMID: 32702298, PMCID: PMC7445431.
O’ReillyO.’R.PO’ReillyO.’R., „A Phase III study to investigate a vaccine against COVID-19", „ISRCTN”, 2020, DOI: 10.1186/ISRCTN89951424.
MerrynM.VoyseyMerrynM. i inni, Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials, „The Lancet”, 397 (10277), 2021, s. 881–891, DOI: 10.1016/S0140-6736(21)00432-3, PMID: 33617777, PMCID: PMC7894131 [dostęp 2021-05-25](ang.).
IngridI.TorjesenIngridI., Covid-19: First doses of vaccines in Scotland led to a substantial fall in hospital admissions, „British Medical Journal”, 372, 2021, art. nr n523, DOI: 10.1136/bmj.n523, PMID: 33619037 [dostęp 2021-05-25](ang.).
MerrynM.VoyseyMerrynM. i inni, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, „The Lancet”, 397 (10269), 2021, s. 99–111, DOI: 10.1016/S0140-6736(20)32661-1, ISSN0140-6736, PMID: 33306989, PMCID: PMC7723445 [dostęp 2021-02-04](ang.).
Pedro MP.M.FolegattiPedro MP.M. i inni, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial”., „The Lancet”, 396 (10249), 2020, s. 467–478, DOI: 10.1016/S0140-6736(20)31604-4, PMID: 32702298, PMCID: PMC7445431.
MerrynM.VoyseyMerrynM. i inni, Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials, „The Lancet”, 397 (10277), 2021, s. 881–891, DOI: 10.1016/S0140-6736(21)00432-3, PMID: 33617777, PMCID: PMC7894131 [dostęp 2021-05-25](ang.).
IngridI.TorjesenIngridI., Covid-19: First doses of vaccines in Scotland led to a substantial fall in hospital admissions, „British Medical Journal”, 372, 2021, art. nr n523, DOI: 10.1136/bmj.n523, PMID: 33619037 [dostęp 2021-05-25](ang.).
MerrynM.VoyseyMerrynM. i inni, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, „The Lancet”, 397 (10269), 2021, s. 99–111, DOI: 10.1016/S0140-6736(20)32661-1, ISSN0140-6736, PMID: 33306989, PMCID: PMC7723445 [dostęp 2021-02-04](ang.).